)
Product Pipeline
Focused on Innovation
CSL Behring is a global leader in developing and delivering high quality medicines that treat people with rare and serious diseases. Working every day as if people’s lives depend on it, CSL’s R&D fuels the company’s sustainable growth by advancing world-class science, technology and collaboration. Our strong R&D pipeline utilises its expertise in plasma fractionation, recombinant technology, and cell and gene therapy to develop and deliver innovative medicines that address unmet medical needs or enhance current treatments in five Therapeutic Areas - Immunology, Haematology, Cardiovascular and Metabolic, Respiratory and Transplant. Our R&D portfolio focuses on innovation in new products, improved products and manufacturing expertise ensuring our continued growth.
Core Capabilities
as demonstrated in our product pipeline
Research / Pre-Clinical
Clinical Development
Registration / Post-Launch
Improved Fibrinogen
Improved liquid formulation.
CSL787 Nebulised Ig
Research program on Nebulised Ig for the potential prevention of chronic respiratory tract infections and progression of chronic lung disease
P. gingivalis POD* OH-CRC
Vaccine to prevent and treat the severe gum disease Periodontitis, caused by the bacterium Porphyromonas gingivalis.
* Partnered Project
aQIVc
MF59 adjuvant plus FLUCELVAX® antigen.
Discovery Projects
Discovery projects aiming to grow CSL’s R&D pipeline in our five Therapeutic Areas.
HIZENTRA® DM
HIZENTRA™, 20% subcutaneous immunoglobulin, for the treatment and long-term maintenance therapy of adults with Dermatomyositis (DM).
HIZENTRA® SSc
HIZENTRA™, 20% subcutaneous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).
PRIVIGEN® SSc
PRIVIGEN®, 10% intravenous immunoglobulin, for the treatment of Systemic Sclerosis (SSc).
HAEGARDA® Japan
Self-administered, subcutaneous C1-esterase inhibitor (human) for routine prophylaxis to prevent HAE attacks.
CSL730* rFc Multimer
Novel recombinant human Fc multimer for treatment of patients with immune complex-mediated autoimmune diseases. Developed in collaboration with Momenta Pharmaceuticals.
* Partnered Project
CSL312 Anti-FXIIa in HAE
A humanised anti-factor XIIa monoclonal antibody in development for use in multiple indications including as a subcutaneous therapy for HAE with the potential for administration once every two to three weeks.
CSL334 IL-13R* ASLAN
Monoclonal antibody targeting IL-13Rα1 for the treatment of atopic dermatitis. Licensed to ASLAN Pharmaceuticals.
* Partnered Project
CSL324 Anti-G-CSFR
Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor receptor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases.
Mavrilimumab Anti-GM-CSFR*
Recombinant monoclonal antibody against the granulocyte macrophage colony-stimulating factor receptor as a potential treatment for inflammatory diseases.
* Partnered Project
CSL889 Hemopexin in SCD
Research program on plasma-derived Hemopexin for the potential treatment of Sickle Cell Disease.
CSL200 γ-Globin Gene Therapy in SCD
γ-Globin Gene Therapy for Severe Sickle Cell Disease (SCD).
CSL630 pdFVIII Ruide
Plasma-derived Human Factor VIII manufactured in China through the acquisition of Wuhan Zhong Yuan Rui De Biological Products Co. Ltd. (Ruide).
CSL312 Anti-FXIIa in Thrombosis
A humanized, anti-factor XIIa monoclonal antibody in development for the prevention of contact-activated thrombosis without bleeding risk.
CSL311 Anti-Beta Common
Fully human monoclonal antibody inhibiting GM-CSF, IL-3 and IL-5 signalling by neutralising the ß-common receptor for the potential treatment of complex inflammatory diseases.
CSL346 Anti-VEGF-B
A humanised mAb that antagonises VEGF-B and is administered via subcutaneous injection either as a standalone therapy or in combination with other agents for the potential treatment of diabetic nephropathy, or other conditions associated with aberrant lipid metabolism.
CSL112 Apo-A1
Novel apolipoprotein A-I infusion therapy developed to reduce the high incidence of early recurrent cardiovascular events that occur in the weeks to months following a heart attack.
CSL964 GvHD Preventation
Prevention of acute Graft versus Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic cell transplant (HCT).
CSL964 GvHD Treatment
Treatment of steroid refractory, acute Graft versus Host Disease (GvHD) in high-risk patients receiving an allogenic hematopoietic cell transplant (HCT).
CSL842 C1-INH AMR
C1-esterase inhibitor (C1-INH) for the treatment of refractory antibody mediated rejection (rAMR) in adult renal transplant recipients.
Clazakizumab (Anti-IL-6 mAb)
Humanized recombinant monoclonal antibody that binds to and inhibits interleukin-6 (IL-6) as a therapeutic option for solid organ transplant rejection.
FLUCELVAX® 6M+
Seasonal cell culture-based, quadrivalent influenza vaccine offering protection against four different strains for use in children 6 months of age and older.
HIZENTRA® CIDP US, Japan, EU, AUS
The first 20% high concentration low volume subcutaneous immunoglobulin for convenient self administration. Approval for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
PRIVIGEN® PID Japan
PRIVIGEN®, 10% intravenous immunoglobulin, for the treatment of primary immune deficiency (PID) indications in Japan.
PRIVIGEN® CIDP US, Japan
PRIVIGEN®, 10% intravenous immunoglobulin, approved for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.
CSL830 C1-INH Subcut, EU
Self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.
HAEGARDA® US
Self-administered subcutaneous C1-esterase inhibitor (human), for routine prophylaxis to prevent HAE attacks in adolescent and adult patients.
KCENTRA® Japan
Lyophilized formulation of plasma-derived concentrate of coagulation factors II, VII, IX, X, Protein C and Protein S used as intravenous administration in patients with acquired deficiency of coagulation factors due to vitamin K antagonist (e.g. Warfarin) therapy.
IDELVION®
Novel, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the treatment of haemophilia B. Delivers high-level protection with up to 14-day dosing in appropriate patients.
AFSTYLA®
Novel long-lasting recombinant factor VIII single-chain therapy for adults and children with haemophilia A.
ZEMAIRA®/RESPREEZA® AAT
Alpha1-Proteinase Inhibitor (Human) for treatment of Alpha- 1 Antitrypsin (AAT) Deficiency.
AFLURIA® QIV 6m+ US, AUS
Seasonal egg-based split viron quadrivalent influenza vaccine registered in the US and Australia for use in children 6 months of age and older.
FLUAD® QIV 65+
Seasonal egg-based, adjuvanted quadrivalent influenza vaccine offering protection against four different strains
Pre-Pandemic Vaccine (aH5N1c)
Pandemic Influenza vaccine, cell based, MF59 adjuvanted, offering protection against H5N1